Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From JHL Biotech
Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely.
Court denies JHL motion to dismiss trade secret theft suit, bars development or sale of biosimilars that rely on information from Genentech documents; trial scheduled to begin in November 2020.
New round of funding allows EdiGene to hire a clinical development executive from Parexel, Teijin Pharma appoints a president, while Astellas has a new president of pharmaceutical technology.
Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft
Government indicts former Genentech employees, one of whom admits to secretly working at JHL Biotech and downloading confidential documents. Trade secrets theft case is unusual in two ways: its extraordinary scope and detail and the filing of criminal charges.
- Contract Research, Toxicology Testing-CRO
- Group Purchasing
- Home Infusion
- Generic Drugs
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes